###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
ApoE polymorphisms in narcolepsy
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE4</italic>
###xml 264 267 <span type="species:ncbi:9606">men</span>
Narcolepsy is a common neuropsychiatric disorder characterized by increased daytime sleepiness, cataplexy and hypnagogic hallucinations. Deficiency of the hypocretin neurotransmitter system was shown to be involved in the pathogenesis of narcolepsy in animals and men. There are several hints that neurodegeneration of hypocretin producing neurons in the hypothalamus is the pathological correlate of narcolepsy. The ApoE4 allele is a major contributing factor to early-onset neuronal degeneration in Alzheimer disease and other neurodegenerative diseases as well.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
To clarify whether the ApoE4 phenotype predisposes to narcolepsy or associates with an earlier disease onset, we have genotyped the ApoE gene in 103 patients with narcolepsy and 101 healthy controls.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 63 70 <span type="species:ncbi:9606">patient</span>
###xml 182 189 <span type="species:ncbi:9606">patient</span>
The frequency of the E4 allele of the ApoE gene was 11% in the patient and 15% in the control groups. Furthermore, the mean age of onset did not differ between the ApoE4+ and ApoE4- patient groups.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE4</italic>
Our results exclude the ApoE4 allele as a major risk factor for narcolepsy.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR2</italic>
###xml 433 440 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR2</italic>
###xml 440 441 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 446 459 434 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1*0602</italic>
###xml 459 460 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 461 462 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 463 464 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 580 581 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 736 746 724 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hypocretin</italic>
###xml 802 803 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 933 954 921 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hypocretin-receptor 2</italic>
###xml 961 962 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1023 1031 1011 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">decresed</italic>
###xml 1051 1052 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1086 1105 1074 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hypocretin receptor</italic>
###xml 1238 1254 1226 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">preprohypocretin</italic>
###xml 1261 1262 1249 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1317 1333 1305 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">preprohypocretin</italic>
###xml 1390 1391 1378 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1578 1579 1566 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1580 1581 1568 1569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 690 696 <span type="species:ncbi:10090">Murine</span>
###xml 784 789 <span type="species:ncbi:9606">human</span>
###xml 1126 1132 <span type="species:ncbi:9606">humans</span>
###xml 1143 1150 <span type="species:ncbi:9606">patient</span>
###xml 1493 1501 <span type="species:ncbi:9606">patients</span>
Narcolepsy is a frequent debilitiating neuropsychiatric disorder characterized by increased daytime sleepiness, cataplectic episodes and hypnopompic and hypnagogic hallucinations. The occurence of narcolepsy is sporadic; however, a proportion of cases is familial with an autosomal-dominant type of inheritance. In contrast to the normal population with an HLA-DR2 allele frequency of approximately30%, over 90% of narcoleptics type HLA-DR2+ and HLA-DQB1*0602+[1,2]. The biological significance of this association remains elusive implicating autoimmune aspects in the ethiology [3]. In two animal models the involvement of the hypocretin (orexin) neurotransmitter system was demonstrated. Murine narcolepsy induced by knocking out the hypocretin gene shows symptoms corresponding to human narcolepsy [4]. Dobermann pincher and Labrador breeds with autosomal recessively inherited narcolepsy each share a splice-site mutation in the hypocretin-receptor 2 gene [5]. Although hypocretin levels in CSF of most narcoleptics is decresed or not detectable [6], no causative mutations in both hypocretin receptor genes were found in humans. A single patient with atypical early-onset narcolepsy carries a dominant signal peptide mutation in the preprohypocretin gene [7]. Furthermore a rare sequence variant in the 5'UTR of preprohypocretin gene has been shown to be a risk factor for narcolepsy [8]. Recent reports describe a nearly complete loss of hypocretinergic neurons in brains of narcoleptic patients as well as scar tissue normally occupied by the hypocretin-producing cells [7,9].
###end p 10
###begin p 11
###xml 45 47 45 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE4</italic>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 574 576 574 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
Among several neurodegenerative diseases the E4 allele of the ApoE gene has been recognized as a predisposing genetic risk factor mainly influencing the age of manifestation of M. Alzheimer. The ApoE protein is a component of the VLDL particles and chylomicrons and its primary role is lipid transport [10,11]. The pathophysiological effect of ApoE4 in neurodegeneration is not clarified yet and may possibly involve diminished neuroprotection against amyloid depositions, reactive oxygen species or exitotoxins [12]. We have tested the hypothesis of the involvement of the E4 allele of ApoE in the etiology of narcolepsy.
###end p 11
###begin title 12
Methods
###end title 12
###begin p 13
###xml 203 257 203 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Diagnostic and Statistical Manual of Mental Disorders,</italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 532 544 <span type="species:ncbi:9606">participants</span>
Patients were recruited from the University Hospital in Mainz and St. Josef Hospital in Bochum, Germany. All but two patients suffered from cataplexies. All patients fulfilled diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) and the International Classification of Sleep Disease of the American Sleep Disorders Association for narcolepsy. For further details see Gencik et al. 2000 [8]. The control group was composed of neurologically investigated 101 healthy individuals. All participants gave written, informed consent.
###end p 13
###begin p 14
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 160 161 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 224 225 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 294 295 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 329 330 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
ApoE genotyping was performed as described [13]. The HLA-DR2 status of the patients was determined previously. 94 patients typed HLA-DR2+ and 9 patients HLA-DR2-[8]. Genotype and allele frequencies were compared with the Chi2-significance test. The age of onset was known in 60 patients with E4- genotypes and 13 patients with E4+genotypes, these data were compared by the Mann Whitney test.
###end p 14
###begin title 15
Results and discussion
###end title 15
###begin p 16
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR2</italic>
###xml 153 156 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 171 173 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 210 226 206 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">preprohypocretin</italic>
###xml 233 234 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Until now, only a few factors were recognized to predispose to narcolepsy. It is the major association with the HLA-DR2 allele on the one hand. Specific TNFalpha alleles [14] as well as the 3250T allele of the preprohypocretin gene [8] are minor contributors to the etiology on the other hand. No exogenous risk factors for narcolepsy have been recognized so far.
###end p 16
###begin p 17
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
###xml 175 179 <span type="species:ncbi:9615">dogs</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Recently, a novel neurotransmitter system was shown to be involved in narcolepsy in the canine disease model and in the orexin knock-out mouse. Autopsy reports of narcoleptic dogs and patients with narcolepsy pointed out possible neurodegenerative processes in areals with hypocretin-producing neurons. Taken together, the pathophysiology of narcolepsy seems to involve an autoimmune driven neurodegeneration of yet unkown cause [3,15].
###end p 17
###begin p 18
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2</italic>
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E3</italic>
###xml 134 136 134 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 552 560 <span type="species:ncbi:9606">patients</span>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
In order to specify the role of ApoE isoforms in narcolepsy, we have determined the allele and genotype frequencies of the E2, E3 and E4 alleles in patients with narcolepsy and healthy controls. Allelic and genotypic frequencies are shown in table 1. No statistically significant differences were detected between nacoleptics, the DR2 subgroups and the controls. Although not significant, a tendentially increased E3 frequency was seen among the DR2+ subgroup of narcoleptics. Furthermore, in 73 narcoleptics exact age of onset could be determined. 60 patients had an non-E4, 13 patients had an E4 phenotype. The manifestation ages were 19.6 +/- 9.9 years (mean +/- SD) and 21.4 +/- 8.6 years for the non-E4 group and E4 group, respectively. The mean difference of 1.8 years were not statistically signifcant (p = 0.44).
###end p 18
###begin p 19
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Allele and genotype frequencies of the ApoE gene in narcolespy patients and controls.
###end p 19
###begin title 20
Conclusion
###end title 20
###begin p 21
The presented results indicate, that the E4 isotype of the ApoE protein, which is an important risk factor for complex traits like alzheimer disease, parkinsonism and other neurodegenerative disorders is not involved in pathophosiological processes in narcolepsy.
###end p 21
###begin title 22
Declaration of competing interests
###end title 22
###begin p 23
None declared.
###end p 23
###begin title 24
Pre-publication history
###end title 24
###begin p 25
The pre-publication history for this paper can be accessed here:
###end p 25
###begin p 26

###end p 26
###begin article-title 27
0MIM 161400
###end article-title 27
###begin article-title 28
Complex HLA-DR and - DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
###end article-title 28
###begin article-title 29
Narcolepsy and the HLA system.
###end article-title 29
###begin article-title 30
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
###end article-title 30
###begin article-title 31
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
###end article-title 31
###begin article-title 32
###xml 34 39 <span type="species:ncbi:9606">human</span>
Hypocretin (orexin) deficiency in human narcolepsy.
###end article-title 32
###begin article-title 33
###xml 99 104 <span type="species:ncbi:9606">human</span>
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
###end article-title 33
###begin article-title 34
A prepro-orexin gene polymorphism is associated with narcolepsy.
###end article-title 34
###begin article-title 35
###xml 40 45 <span type="species:ncbi:9606">human</span>
Reduced number of hypocretin neurons in human narcolepsy.
###end article-title 35
###begin article-title 36
Apolipoprotein E: Far more than a lipid transport protein.
###end article-title 36
###begin article-title 37
OMIM 107741
###end article-title 37
###begin article-title 38
Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond.
###end article-title 38
###begin article-title 39
Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.
###end article-title 39
###begin article-title 40
###xml 126 131 <span type="species:ncbi:9606">human</span>
Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy.
###end article-title 40
###begin article-title 41
###xml 34 42 <span type="species:ncbi:9606">patients</span>
In vivo and in vitro variables in patients with narcolepsy and HLA-DR2 matched controls.
###end article-title 41

